Alzheimer’s drug from Eisai, Biogen shows promise in large trial

Eisai Co. and Biogen Inc. said their experimental Alzheimer’s disease drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects for approval.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.